Measurable residual disease (MRD) has been a hot topic of interest due to its potential applications in the clinical setting. MRD measurement can help determine treatment efficacy, disease prognosis and guide disease management. In this podcast, Bijal Shah of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Richard Dillon from King’s College London, Todd Druley of Washington University School of Medicine in St. Louis and Ola Landgren of Memorial Sloan Kettering Cancer Center explore the exciting realm of MRD.
The role of MRD as a prognostic factor, the novel technologies that can be used to detect MRD, the next steps in utilizing this measure and MRD measurement as a strategy for treatment-free survival are among the stimulating areas considered. This footage was recorded at the International Workshop on Acute Leukemias (iwAL) 2018, the British Society for Haematology (BSH) 2018 Annual Meeting, the American Society for Hematology (ASH) Annual Meeting and Exposition 2016 and 2017, and the European Hematology Association (EHA) Congress 2018.
The post Focus on MRD: current landscape and future questions in hemonc appeared first on VJHemOnc.
